Access
This article is part of Nature's premium content.
Published online 19 June 2001 | Nature | doi:10.1038/news010621-3
News
Double or quit for cancer drug
Genetic patterns predict chemotherapy success
Double DNA you win, triple you lose: some cancer patients with two rather than three key DNA repeats respond better to a widely used chemotherapy drug, researchers suggest1. Their findings raise hopes that gene-tailored medicine will make treatment less of a gamble.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
There are currently no comments.
